MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Deferred Tax Assets / Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Deferred Tax Assets / Liabilities | ₹1,705 Cr | ₹8.68 Cr | ₹48 Cr | ₹16 Cr | ₹-36 Cr |
What is the latest Deferred Tax Assets / Liabilities ratio of MANKIND PHARMA ?
| Year | Deferred Tax Assets / Liabilities |
|---|---|
| Mar2025 | ₹1,705 Cr |
| Mar2024 | ₹8.68 Cr |
| Mar2023 | ₹48 Cr |
| Mar2022 | ₹16 Cr |
| Mar2021 | ₹-36 Cr |
How is Deferred Tax Assets / Liabilities of MANKIND PHARMA Trending?
| Years | Deferred Tax Assets / Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,705 Cr | 19,538.48 | |
| Mar2024 | ₹8.68 Cr | -81.74 | |
| Mar2023 | ₹48 Cr | 191.02 | |
| Mar2022 | ₹16 Cr | Positive | |
| Mar2021 | ₹-36 Cr | - | |
Compare Deferred Tax Assets / Liabilities of peers of MANKIND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MANKIND PHARMA | ₹98,343.4 Cr | -1.4% | -2.2% | 0.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹405,452.0 Cr | -0.3% | 6% | -10.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,089.0 Cr | 3.9% | 18.6% | 14.5% | Stock Analytics | |
| CIPLA | ₹121,299.0 Cr | -5.2% | NA | 2.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹120,456.0 Cr | -1% | -1.2% | 8.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,965.9 Cr | -6.8% | -2.1% | -8.4% | Stock Analytics | |
MANKIND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -1.4% |
-2.2% |
0.7% |
| SENSEX | -0.3% |
4.5% |
5.7% |
You may also like the below Video Courses